Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report published on Thursday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reissued a neutral rating and set a $1.00 price target on shares of Cytosorbents in a report on Friday, March 15th.

Cytosorbents Price Performance

Shares of CTSO traded up $0.06 during mid-day trading on Thursday, reaching $0.88. The company had a trading volume of 109,450 shares, compared to its average volume of 93,292. The company has a current ratio of 1.77, a quick ratio of 1.51 and a debt-to-equity ratio of 0.11. Cytosorbents has a twelve month low of $0.78 and a twelve month high of $4.29. The company’s 50-day moving average is $0.91 and its 200-day moving average is $1.14.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. The firm had revenue of $8.67 million for the quarter, compared to analysts’ expectations of $9.29 million. Cytosorbents had a negative return on equity of 120.24% and a negative net margin of 78.43%. On average, research analysts anticipate that Cytosorbents will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently bought and sold shares of CTSO. Key Client Fiduciary Advisors LLC grew its holdings in shares of Cytosorbents by 188.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after purchasing an additional 22,557 shares during the last quarter. Chicago Partners Investment Group LLC grew its holdings in Cytosorbents by 84.0% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 36,358 shares of the medical research company’s stock worth $67,000 after acquiring an additional 16,598 shares during the last quarter. Raymond James & Associates acquired a new stake in Cytosorbents in the 4th quarter valued at about $56,000. Sargent Investment Group LLC increased its position in Cytosorbents by 4.1% in the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after acquiring an additional 51,699 shares in the last quarter. Finally, Neuberger Berman Group LLC raised its stake in shares of Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares during the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.